In the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application:

Claims **1-40** (Cancelled).

Claim **41** (Currently Amended) A method of treating ~~or preventing a nervous system disorder~~ fibromyalgia and other somatoform disorders, the method comprising the step of administering a therapeutically effective dose of racemic reboxetine or a pharmaceutically acceptable salt thereof to an individual ~~, wherein said disorder is selected from the group consisting of at least one of an adjustment disorder, an age-associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder due to general medical conditions, bipolar disorder, bulimia nervosa, chronic fatigue syndrome, chronic or acute stress, chronic pain, cyclothymic disorder, dysthymic disorder, fibromyalgia and other somatoform disorders, incontinence, mania, migraine headaches, obesity, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder, seasonal affective disorder, a sleep disorders, a specific developmental disorders, SSRI "poop-out" syndrome, and TIC disorders~~ .

Claim **42** (Cancelled).

Claim **43** (Cancelled).

Claim **44** (Original) The method of claim **41** wherein the reboxetine is administered to the individual in an amount of about 2 to about 20 mg/day.

Claim **45** (Original) The method of claim **44** wherein the reboxetine is administered to the individual in an amount of about 4 to about 10 mg/day.

Claim **46** (Original) The method of claim **45** wherein the reboxetine is administered to the individual in an amount of about 6 to about 10 mg/day.

Claim **47** (Original) The method of claim **41** wherein said reboxetine is administered orally, parenterally, topically, transdermally, rectally, or vaginally.

Claim **48** (Original) The method of claim **47** wherein said reboxetine is orally administered with a pharmaceutically acceptable carrier comprising at least one of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, and wetting agent.

Claim **49** (Original) The method of claim **48** wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **50** (Original) The method of claim **47** wherein said reboxetine is parentarally administered subcutaneously, intraveously, or intramuscularly.

Claim **51** (Original) The method of claim **41** wherein the pharmaceutically acceptable salt is methanesulfonate salt.

Claim **52** (Cancelled).

Claim **53** (Cancelled).